quinapril has been researched along with Arteriosclerosis, Coronary in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (35.71) | 18.2507 |
| 2000's | 9 (64.29) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gans, RO; Gurné, O; Tervaert, JW; van Geel, PP; van Gilst, WH; van Haelst, PL; Veeger, NJ | 1 |
| Annis, K; Chaitman, B; Davies, R; Ducharme, A; Freedman, SB; Haber, HE; Lenis, J; Ma, P; Pepine, CJ; Pitt, B; Pressler, ML; Rouleau, JL; Thadani, U | 1 |
| Iwaniec, T; Potaczek, DP; Szczeklik, A; Undas, A | 1 |
| Abe, Y; Hirosaka, A; Hisa, S; Igarashi, M; Kijima, M; Komatsu, N; Maehara, K; Maruyama, Y; Mitsugi, M; Ohwada, T; Tsuda, T; Ujiie, Y; Yaoita, H | 1 |
| Celinska-Löwenhoff, M; Löwenhoff, T; Szczeklik, A; Undas, A | 1 |
| Baillot, R; Block, P; Calciu, CD; Chocron, S; Johnstone, D; Myers, MG; Rouleau, JL; van Gilst, WH; Warnica, JW | 1 |
| Brummel-Ziedins, KE; Bryniarski, L; Mann, KG; Potaczek, DP; Stobierska-Dzierzek, B; Szczeklik, A; Undas, A | 1 |
| Dinsmore, RE; Lees, RS; Pitt, B; Texter, M; Uprichard, AC | 1 |
| Pepine, CJ | 1 |
| Hori, M; Hoshida, S; Kawahara, K; Kuzuya, T; Yamashita, N | 1 |
| Cashin-Hemphill, L; Chan, RC; Dinsmore, RE; Holmvang, G; Lees, RS; Pitt, B | 1 |
| Bass, T; Cashin-Hemphill, L; Feldman, R; Ferrari, R; Haber, H; Lees, RS; Mudra, H; O'Neill, B; Pepine, C; Pitt, B; Schwartz, L; Texter, M; Uprichard, A | 1 |
| Mancini, GB | 1 |
| Pitt, B | 1 |
1 review(s) available for quinapril and Arteriosclerosis, Coronary
| Article | Year |
|---|---|
Rationale for ACE inhibition as an anti-ischaemic therapy.
Topics: Angiotensin-Converting Enzyme Inhibitors; Cholesterol, LDL; Coronary Artery Disease; Coronary Disease; Endothelium, Vascular; Humans; Isoquinolines; Myocardial Ischemia; Quinapril; Randomized Controlled Trials as Topic; Survival Rate; Tetrahydroisoquinolines | 1998 |
10 trial(s) available for quinapril and Arteriosclerosis, Coronary
| Article | Year |
|---|---|
Long term angiotensin converting enzyme-inhibition in patients after coronary artery bypass grafting reduces levels of soluble intercellular cell adhesion molecule-1.
Topics: Angiotensin-Converting Enzyme Inhibitors; C-Reactive Protein; Coronary Artery Bypass; Coronary Artery Disease; Double-Blind Method; Female; Humans; Intercellular Adhesion Molecule-1; Isoquinolines; Male; Middle Aged; Quinapril; Tetrahydroisoquinolines | 2003 |
Effects of angiotensin-converting enzyme inhibition on transient ischemia: the Quinapril Anti-Ischemia and Symptoms of Angina Reduction (QUASAR) trial.
Topics: Angina Pectoris; Angiotensin-Converting Enzyme Inhibitors; Coronary Artery Disease; Double-Blind Method; Electrocardiography; Female; Humans; Male; Middle Aged; Myocardial Ischemia; Quinapril; Tetrahydroisoquinolines | 2003 |
Effects of angiotensin-converting enzyme inhibitors or an angiotensin receptor blocker in combination with aspirin and cilostazol on in-stent restenosis.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cilostazol; Coronary Artery Disease; Coronary Restenosis; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Perindopril; Platelet Aggregation Inhibitors; Quinapril; Stents; Tetrahydroisoquinolines; Tetrazoles | 2006 |
Statins, fenofibrate, and quinapril increase clot permeability and enhance fibrinolysis in patients with coronary artery disease.
Topics: Aged; Atorvastatin; Coronary Artery Disease; Fenofibrate; Fibrinolysis; Genotype; Heptanoic Acids; Humans; Male; Permeability; Pyrroles; Quinapril; Simvastatin; Tetrahydroisoquinolines; Thrombin; Thrombosis | 2006 |
Angiotensin-converting enzyme inhibition in patients with coronary artery disease and preserved left ventricular function Ischemia Management with Accupril post-bypass graft via inhibition of angiotensin-converting enzyme (IMAGINE) compared with the other
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Coronary Artery Bypass; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Quinapril; Randomized Controlled Trials as Topic; Tetrahydroisoquinolines; Ventricular Function, Left | 2006 |
Atorvastatin and quinapril inhibit blood coagulation in patients with coronary artery disease following 28 days of therapy.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Anticholesteremic Agents; Atorvastatin; Blood Coagulation; Blood Coagulation Factors; Coronary Artery Disease; Double-Blind Method; Evaluation Studies as Topic; Heptanoic Acids; Humans; Male; Middle Aged; Myocardial Infarction; Pyrroles; Quinapril; Risk Factors; Stroke; Tetrahydroisoquinolines; Time Factors | 2006 |
The QUinapril Ischemic Event Trial (QUIET) design and methods: evaluation of chronic ACE inhibitor therapy after coronary artery intervention.
Topics: Adult; Aged; Angioplasty; Angiotensin-Converting Enzyme Inhibitors; Atherectomy; Coronary Artery Disease; Double-Blind Method; Evaluation Studies as Topic; Female; Humans; Incidence; Isoquinolines; Male; Middle Aged; Placebos; Prospective Studies; Quinapril; Tetrahydroisoquinolines | 1993 |
Angiotensin-converting enzyme inhibition as antiatherosclerotic therapy: no answer yet. QUIET Investigators. QUinapril Ischemic Event Trial.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Confounding Factors, Epidemiologic; Coronary Angiography; Coronary Artery Disease; Female; Humans; Isoquinolines; Lipids; Male; Middle Aged; Quinapril; Tetrahydroisoquinolines; Treatment Outcome | 1999 |
The QUinapril Ischemic Event Trial (QUIET): evaluation of chronic ACE inhibitor therapy in patients with ischemic heart disease and preserved left ventricular function.
Topics: Adult; Aged; Angioplasty; Angiotensin-Converting Enzyme Inhibitors; Coronary Angiography; Coronary Artery Disease; Disease Progression; Female; Humans; Incidence; Isoquinolines; Male; Middle Aged; Myocardial Ischemia; Proportional Hazards Models; Quinapril; Survival Analysis; Tetrahydroisoquinolines; Treatment Outcome; Ventricular Function, Left | 2001 |
The Quinapril Ischemic Event Trial (QUIET).
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Coronary Artery Disease; Humans; Isoquinolines; Myocardial Ischemia; Quinapril; Tetrahydroisoquinolines | 1992 |
3 other study(ies) available for quinapril and Arteriosclerosis, Coronary
| Article | Year |
|---|---|
The angiotensin-converting enzyme gene insertion/deletion polymorphism and effects of quinapril and atorvastatin on haemostatic parameters in patients with coronary artery disease.
Topics: Alleles; Angiography; Angiotensin-Converting Enzyme Inhibitors; Atorvastatin; Blood Pressure; Coronary Artery Disease; Fibrin Fibrinogen Degradation Products; Genotype; Hemostasis; Heptanoic Acids; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Peptidyl-Dipeptidase A; Polymorphism, Genetic; Pyrroles; Quinapril; Risk; Tetrahydroisoquinolines; Time Factors | 2005 |
Amelioration by quinapril of myocardial infarction induced by coronary occlusion/reperfusion in a rabbit model of atherosclerosis: possible mechanisms.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Aorta; Arterial Occlusive Diseases; Coronary Artery Disease; Cyclic GMP; Disease Models, Animal; Enzyme Inhibitors; Hemodynamics; Isoquinolines; Leukocytes; Male; Myocardial Infarction; Myocardial Ischemia; Myocardial Reperfusion Injury; Myocardium; NG-Nitroarginine Methyl Ester; Nitric Oxide Synthase; P-Selectin; Peroxidase; Quinapril; Rabbits; Receptor, Bradykinin B2; Receptors, Bradykinin; Tetrahydroisoquinolines; Ventricular Fibrillation | 1999 |
Angiotensin converting enzyme inhibitors and restenosis: let's stop teasing ourselves.
Topics: Angiotensin-Converting Enzyme Inhibitors; Coronary Artery Disease; Coronary Restenosis; Endothelium, Vascular; Humans; Isoquinolines; Quinapril; Tetrahydroisoquinolines | 2001 |